HUP0003547A2 - Akut tüdőelváltozás és fibrózis kezelése alfavbéta6-antagonistákkal - Google Patents
Akut tüdőelváltozás és fibrózis kezelése alfavbéta6-antagonistákkalInfo
- Publication number
- HUP0003547A2 HUP0003547A2 HU0003547A HUP0003547A HUP0003547A2 HU P0003547 A2 HUP0003547 A2 HU P0003547A2 HU 0003547 A HU0003547 A HU 0003547A HU P0003547 A HUP0003547 A HU P0003547A HU P0003547 A2 HUP0003547 A2 HU P0003547A2
- Authority
- HU
- Hungary
- Prior art keywords
- treatment
- fibrosis
- lung lesions
- acute lung
- antagonists
- Prior art date
Links
- 230000004761 fibrosis Effects 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 206010069351 acute lung injury Diseases 0.000 title 1
- 208000005069 pulmonary fibrosis Diseases 0.000 title 1
- 210000004072 lung Anatomy 0.000 abstract 5
- 230000003902 lesion Effects 0.000 abstract 3
- 206010016654 Fibrosis Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108010006654 Bleomycin Proteins 0.000 abstract 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 abstract 1
- 206010049771 Shock haemorrhagic Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 201000005008 bacterial sepsis Diseases 0.000 abstract 1
- 229960001561 bleomycin Drugs 0.000 abstract 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000000981 epithelium Anatomy 0.000 abstract 1
- 210000003238 esophagus Anatomy 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000002574 poison Substances 0.000 abstract 1
- 231100000614 poison Toxicity 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
A találmány az akut tüdőelváltozás kezelési eljárásaira éskészítményeire vonatkozik, mint amilyen például a bakteriálisszepszisből származó tüdőelváltozás, vérzéses sokk, méregbelégzés és ableomicin vagy egyéb gyógyszer által előidézett tüdőelváltozás.Ezenkívül a találmány szerinti készítmények alkalmazhatók ahámszövettel rendelkező szervekben, mint a tüdőben, a májban, avesében, a húgyhólyagban és a nyelőcsőben fellépő fibrózis kezelésére.A találmány szerinti kezelés során, illetve gyógyszerkészítménnyelavb6 antagonistát adagolnak a bleomicinkezelés előtt vagy alatt (aterápia megelőző vagy kezelő jellegétől függően), ami megakadályozzaaz avb6 integrin és a ligandum közötti kölcsönhatást, ezáltal atüdőtrauma és -fibrózis kifejlődését. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5506097P | 1997-08-08 | 1997-08-08 | |
PCT/US1998/016439 WO1999007405A1 (en) | 1997-08-08 | 1998-08-07 | TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF αvβ6 |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0003547A2 true HUP0003547A2 (hu) | 2001-02-28 |
HUP0003547A3 HUP0003547A3 (en) | 2002-05-28 |
HU228900B1 HU228900B1 (en) | 2013-06-28 |
Family
ID=21995323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0003547A HU228900B1 (en) | 1997-08-08 | 1998-08-07 | Treatment of acute lung injury and fibrosis with antagonists of alphavbetha6 |
Country Status (23)
Country | Link |
---|---|
US (5) | US20020004482A1 (hu) |
EP (3) | EP1930022B1 (hu) |
JP (2) | JP2001513333A (hu) |
KR (1) | KR100586202B1 (hu) |
CN (1) | CN1267224A (hu) |
AT (3) | ATE410179T1 (hu) |
AU (1) | AU739283B2 (hu) |
BR (1) | BR9814040A (hu) |
CA (1) | CA2297736A1 (hu) |
CY (2) | CY1110462T1 (hu) |
CZ (1) | CZ299768B6 (hu) |
DE (2) | DE69828614T2 (hu) |
DK (2) | DK1504764T3 (hu) |
EE (1) | EE04752B1 (hu) |
ES (3) | ES2235350T3 (hu) |
HU (1) | HU228900B1 (hu) |
IL (2) | IL134288A0 (hu) |
NZ (2) | NZ515955A (hu) |
PL (2) | PL199014B1 (hu) |
PT (3) | PT1930022E (hu) |
RU (1) | RU2221589C2 (hu) |
TR (2) | TR200000374T2 (hu) |
WO (1) | WO1999007405A1 (hu) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962643A (en) * | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
DE69828614T2 (de) * | 1997-08-08 | 2006-02-09 | The Regents Of The University Of California, Oakland | Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6 |
CN1332714C (zh) * | 1999-04-22 | 2007-08-22 | 比奥根艾迪克Ma公司 | 整联蛋白α4亚单位的拮抗剂在制备治疗纤维变性的药物组合物中的用途 |
DE19929410A1 (de) * | 1999-06-26 | 2000-12-28 | Merck Patent Gmbh | Inhibitoren des Integrins avß6 |
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
AUPR230500A0 (en) * | 2000-12-22 | 2001-01-25 | University Of Newcastle Research Associates Limited, The | A method of modulating map kinase mediated cellular activity and agents useful in same |
WO2002088307A2 (en) * | 2001-04-30 | 2002-11-07 | Eli Lilly And Company | Humanized antibodies |
WO2003100033A2 (en) * | 2002-03-13 | 2003-12-04 | Biogen Idec Ma Inc. | ANTI-αvβ6 ANTIBODIES |
WO2003087340A2 (en) * | 2002-04-12 | 2003-10-23 | Raven Biotechnologies, Inc. | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
PT1734996E (pt) * | 2004-04-02 | 2013-07-18 | Univ California | Métodos e composição para tratamento e prevenção de doenças associadas a integrina αvβ5 |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
US8795668B2 (en) * | 2005-12-23 | 2014-08-05 | The Regents Of The University Of Michigan | Methods for treating pulmonary fibrosis |
BRPI0714381A2 (pt) | 2006-07-10 | 2013-03-05 | Biogen Idec Inc | composiÇÕes e mÉtodos para inibir crescimento de cÂnceres deficientes em smad4 |
ES2746925T3 (es) * | 2006-08-03 | 2020-03-09 | Medimmune Ltd | Anticuerpos dirigidos hacia alfaVbeta6 y uso de los mismos |
JP2010506944A (ja) * | 2006-10-19 | 2010-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インテグリンαVβ6のアンタゴニストを用いる慢性喘息の処置および予防 |
HUE025283T2 (hu) | 2007-08-02 | 2016-03-29 | Gilead Biologics Inc | LOX és LOX2 inhibitorok és azok felhasználása |
KR101046317B1 (ko) * | 2008-07-04 | 2011-07-05 | 이종대 | 조력발전 방법 및 그 장치 |
US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
CN102481347A (zh) | 2009-07-24 | 2012-05-30 | 加州大学董事会 | 治疗和预防整合素αvβ5相关疾病的方法及组合物 |
CA2771702A1 (en) | 2009-08-21 | 2011-02-24 | Gilead Biologics, Inc. | Catalytic domains from lysyl oxidase and loxl2 |
NZ598464A (en) * | 2009-08-21 | 2014-07-25 | Gilead Biologics Inc | Methods and compositions for treatment of pulmonary fibrotic disorders |
KR20130008021A (ko) * | 2010-02-04 | 2013-01-21 | 길리아드 바이오로직스, 인크. | 리실 산화효소-유사 2 (loxl2)에 결합하는 항체, 및 그를 위한 사용 방법 |
AU2013221585B2 (en) | 2012-02-17 | 2017-03-30 | Seagen Inc. | Antibodies to integrin alphavbeta6 and use of same to treat cancer |
WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
US10035860B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
EP2784511A1 (en) | 2013-03-27 | 2014-10-01 | Universität Zürich | Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma |
JP6104312B2 (ja) * | 2014-06-19 | 2017-03-29 | 日東電工株式会社 | 組織再生促進剤 |
KR20200044066A (ko) | 2017-08-22 | 2020-04-28 | 바이오젠 엠에이 인코포레이티드 | 항-알파(v)베타(6) 항체를 함유하는 약제학적 조성물 및 투약 요법 |
US11827709B2 (en) | 2019-12-05 | 2023-11-28 | Seagen Inc. | Anti-AVB6 antibodies and antibody-drug conjugates |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5654270A (en) * | 1988-06-28 | 1997-08-05 | La Jolla Cancer Research Foundation | Use of fibromodulin to prevent or reduce dermal scarring |
JPH04503951A (ja) | 1988-12-20 | 1992-07-16 | ラ ホヤ キャンサー リサーチ ファウンデーション | 創傷治癒に活性のあるポリペプチド―ポリマー複合体 |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5514788A (en) * | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
US5770565A (en) * | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
US6492332B1 (en) * | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
PT719859E (pt) * | 1994-12-20 | 2003-11-28 | Merck Patent Gmbh | Anticorpo monoclonal anti-alfa v-integrina |
DE69828614T2 (de) * | 1997-08-08 | 2006-02-09 | The Regents Of The University Of California, Oakland | Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6 |
-
1998
- 1998-08-07 DE DE69828614T patent/DE69828614T2/de not_active Expired - Lifetime
- 1998-08-07 PL PL341029A patent/PL199014B1/pl unknown
- 1998-08-07 JP JP2000506994A patent/JP2001513333A/ja not_active Withdrawn
- 1998-08-07 NZ NZ515955A patent/NZ515955A/xx not_active IP Right Cessation
- 1998-08-07 TR TR2000/00374T patent/TR200000374T2/xx unknown
- 1998-08-07 DK DK04022921T patent/DK1504764T3/da active
- 1998-08-07 AU AU87743/98A patent/AU739283B2/en not_active Expired
- 1998-08-07 CA CA002297736A patent/CA2297736A1/en not_active Abandoned
- 1998-08-07 RU RU2000105905/14A patent/RU2221589C2/ru active
- 1998-08-07 PT PT08004714T patent/PT1930022E/pt unknown
- 1998-08-07 PL PL384372A patent/PL201716B1/pl unknown
- 1998-08-07 KR KR1020007001337A patent/KR100586202B1/ko not_active IP Right Cessation
- 1998-08-07 TR TR2002/02323T patent/TR200202323T2/xx unknown
- 1998-08-07 BR BR9814040-0A patent/BR9814040A/pt not_active Application Discontinuation
- 1998-08-07 CN CN98807892A patent/CN1267224A/zh active Pending
- 1998-08-07 AT AT04022921T patent/ATE410179T1/de active
- 1998-08-07 EP EP08004714A patent/EP1930022B1/en not_active Expired - Lifetime
- 1998-08-07 AT AT98939278T patent/ATE286742T1/de active
- 1998-08-07 EP EP98939278A patent/EP0996460B1/en not_active Expired - Lifetime
- 1998-08-07 ES ES98939278T patent/ES2235350T3/es not_active Expired - Lifetime
- 1998-08-07 ES ES08004714T patent/ES2364703T3/es not_active Expired - Lifetime
- 1998-08-07 CZ CZ20000413A patent/CZ299768B6/cs not_active IP Right Cessation
- 1998-08-07 HU HU0003547A patent/HU228900B1/hu unknown
- 1998-08-07 PT PT04022921T patent/PT1504764E/pt unknown
- 1998-08-07 DE DE69840113T patent/DE69840113D1/de not_active Expired - Lifetime
- 1998-08-07 EP EP04022921A patent/EP1504764B1/en not_active Expired - Lifetime
- 1998-08-07 AT AT08004714T patent/ATE511850T1/de active
- 1998-08-07 ES ES04022921T patent/ES2311131T3/es not_active Expired - Lifetime
- 1998-08-07 DK DK08004714.5T patent/DK1930022T3/da active
- 1998-08-07 IL IL13428898A patent/IL134288A0/xx unknown
- 1998-08-07 PT PT98939278T patent/PT996460E/pt unknown
- 1998-08-07 WO PCT/US1998/016439 patent/WO1999007405A1/en active Application Filing
- 1998-08-07 EE EEP200000068A patent/EE04752B1/xx unknown
- 1998-08-07 US US09/130,870 patent/US20020004482A1/en not_active Abandoned
- 1998-08-07 NZ NZ502546A patent/NZ502546A/en not_active IP Right Cessation
-
1999
- 1999-08-02 US US09/365,695 patent/US6316601B1/en not_active Expired - Lifetime
-
2000
- 2000-01-30 IL IL134288A patent/IL134288A/en not_active IP Right Cessation
-
2001
- 2001-03-27 US US09/818,416 patent/US6692741B2/en not_active Expired - Lifetime
-
2004
- 2004-01-09 US US10/754,435 patent/US7150871B2/en not_active Expired - Lifetime
-
2006
- 2006-11-13 US US11/559,172 patent/US7544358B2/en not_active Expired - Fee Related
-
2008
- 2008-08-11 JP JP2008206826A patent/JP2009001587A/ja active Pending
-
2009
- 2009-01-08 CY CY20091100011T patent/CY1110462T1/el unknown
-
2011
- 2011-08-26 CY CY20111100822T patent/CY1111792T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0003547A2 (hu) | Akut tüdőelváltozás és fibrózis kezelése alfavbéta6-antagonistákkal | |
CA2024916A1 (en) | Respiratory disorder medicaments comprising salmeterol and fluticasone propionate | |
CA2362499A1 (en) | Combinations of formoterol and mometasone furoate for asthma | |
HUP0003848A2 (hu) | Budesonid és formoterol új alkalmazása | |
CA2360248A1 (en) | Combinations of formoterol and a tiotropium salt | |
EA200100338A1 (ru) | Способ и устройство для введения действующего вещества в виде аэрозоли в легкие пациента | |
CA2334411A1 (en) | Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma | |
HU9401843D0 (en) | New pharmaceutical composition containing combination of formoterol and budesonide | |
WO2006059108A3 (en) | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES | |
HUP0101411A2 (hu) | 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása | |
CA2277365A1 (en) | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 | |
DE69002718D1 (de) | Medikamente. | |
Lang et al. | Naloxone reversal of morphine-induced biliary colic | |
ATE271852T1 (de) | Verbesserte inhalationspräparate | |
JP2001151677A (ja) | 咽頭用組成物 | |
Hagen | An approach to cough in cancer patients | |
CA2436537A1 (en) | Pharmaceutical compositions comprising tiotropium salts and antihistamines | |
ATE91890T1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
RU1804860C (ru) | Способ лечени хронического бронхита | |
ATE284696T1 (de) | Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten | |
MY111155A (en) | Medicaments | |
Chawla et al. | Effect of anaesthesia on upper respiratory tract bacterial flora. | |
TH16088A (th) | สูตรผสมสำหรับการสูดดม |